Results 151 to 160 of about 8,451 (198)

Recovery of Olfactory Function After Mepolizumab Treatment in Patients with Chronic Rhinosinusitis with Nasal Polyps: Influence of the Number of Surgeries. [PDF]

Biomedicines
Cardesín A, Sogo A, Sansa A, Campos M, Rovira C, Domingo C.   +5 more
europepmc   +1 more source

Eosinophilic Depletion with Benralizumab, Mepolizumab, and Depemokimab: A Modeling Study. [PDF]

J Asthma Allergy
Lukka PB, Penland RC, Brekkan A, Ayoun Alsoud R, So S, Boulton DW.   +5 more
europepmc   +1 more source

Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseases. [PDF]

Front Immunol
Lübke J, Reiter A, Schwaab J.
europepmc   +1 more source

The Use of Biological Therapies in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Current State of Knowledge. [PDF]

J Clin Med
Wrona J, Krupa Z, Zawadzka M, Rydzek J, Muzyka A, Dorobisz K, Pazdro-Zastawny K.   +6 more
europepmc   +1 more source

Biologic Therapies and Biomarkers in Severe Childhood Asthma: A Systematic Review of Omalizumab and Mepolizumab. [PDF]

Pediatr Pulmonol
Gusmão ABF, Marques BO, Gusmão ALF, de Lacerda RT, França APD, Silva EKD, Sousa GS, Pereira MN.   +7 more
europepmc   +1 more source

New perspectives in the treatment of chronic eosinophilic pneumonia in the era of targeted therapies. [PDF]

Front Immunol
Scelfo C, Simonazzi A, Ruggiero P, Pellegrino MR, Facciolongo N.   +4 more
europepmc   +1 more source

Cost-effectiveness analysis of mepolizumab among patients with severe asthma from the Chinese societal perspective. [PDF]

PLoS One
Shi C, Wang Y, Tan C, Zeng X, Liu Q.
europepmc   +1 more source

Biologic therapies targeting type 2 inflammation in NSAID-exacerbated respiratory disease. [PDF]

Front Immunol
Szatkowski P, Çelik GE, Mejza F, Mastalerz L.   +3 more
europepmc   +1 more source

Biologic switching in allergic bronchopulmonary aspergillosis: a scoping review of published clinical experience. [PDF]

J Thorac Dis
Hu Q, Pan X, Chen R, Li G, Li Y, Zheng Y, Zhong Z, Zhang X, Chen Y, Ye J, Duan J, Li J.   +11 more
europepmc   +1 more source

IL-5/IL-5R blockade enables safe non-steroidal anti-inflammatory agent reintroduction in non-steroidal anti-inflammatory exacerbated respiratory disease. [PDF]

Front Immunol
Korkmaz P, Kahveci N, Demir S, Yegit OO, Unal D, Igde MH, Sezgin ME, Aslan AF, Erden B, Bolek L, Atasever MD, Guzel SE, Kamacı ŞÇ, Kaya E, Gelincik A.   +14 more
europepmc   +1 more source